May Hill Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$306K Buy
617
+46
+8% +$20.4K 0.06% 182
2026
Q1
$255K Sell
571
-95
-14% -$44.3K 0.06% 186
2025
Q4
$302K Buy
666
+26
+4% +$11.2K 0.08% 150
2025
Q3
$251K Sell
640
-33
-5% -$13.8K 0.07% 163
2025
Q2
$300K Buy
673
+40
+6% +$18.4K 0.1% 143
2025
Q1
$307K Sell
633
-15
-2% -$6.99K 0.12% 122
2024
Q4
$261K Buy
+648
New +$300K 0.1% 131

Other funds holding VRTX

May Hill Capital's VRTX Position: Q2 2026 in Review

May Hill Capital increased its Vertex Pharmaceuticals (VRTX) stake by 8.1% in Q2 2026, buying an estimated $20.4K and bringing the position to 617 shares worth $306K. The position accounts for 0.06% of the portfolio, ranked #182.

May Hill Capital first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $307K in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • May Hill Capital held 617 shares of Vertex Pharmaceuticals worth $306K as of Q2 2026.
  • May Hill Capital bought 46 Vertex Pharmaceuticals shares in Q2 2026, an estimated $20.4K.
  • Vertex Pharmaceuticals made up 0.06% of May Hill Capital's portfolio in Q2 2026, its #182 holding.
  • May Hill Capital first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • May Hill Capital's Vertex Pharmaceuticals position peaked at $307K in Q1 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on May Hill Capital's 13F filing for Q2 2026, filed 7 Aug 2026.